NCT00150709

A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy

A Multi-Center, Open-Label, Long-Term, Follow-Up Study Of The Safety And Efficacy Of Levetiracetam (Ucb L059) In Children With Epilepsy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 223 (actual)
• Sponsor: UCB Pharma · Industry
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

Open-label study to allow pediatric patients who have participated in prior Levetiracetam (Keppra®) studies to continue their treatment with adequate monitoring and standardized follow-up care until Levetiracetam (Keppra®) is approved for use in children or until the completion of the development program for pediatrics.

Conditions

• Epilepsy, Partial

Interventions

Type	Name	Description
DRUG	Levetiracetam	* Pharmaceutical form: Oral tablets and oral solution * Route of administration: Oral use

Timeline

• Start date: 1998-01-26
• Primary completion: 2006-01-25
• Completion: 2006-01-25
• First posted: 2005-09-08
• Last updated: 2024-02-09
• Results posted: 2024-02-09

Regulatory

• FDA-regulated drug study